Middleton & Co. Inc. MA Sells 575 Shares of Johnson & Johnson (NYSE:JNJ)

Middleton & Co. Inc. MA reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,789 shares of the company’s stock after selling 575 shares during the period. Middleton & Co. Inc. MA’s holdings in Johnson & Johnson were worth $1,789,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in JNJ. Bernard Wealth Management Corp. bought a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $36,000. Highline Wealth Partners LLC boosted its position in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after purchasing an additional 86 shares during the period. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson in the first quarter valued at approximately $49,000. Capital A Wealth Management LLC bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $50,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson in the first quarter worth $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 2.2%

JNJ opened at $171.08 on Tuesday. The company has a market capitalization of $412.02 billion, a P/E ratio of 18.30, a P/E/G ratio of 2.13 and a beta of 0.41. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm’s fifty day moving average price is $157.82 and its two-hundred day moving average price is $156.91. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $171.19.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm’s revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the business earned $2.82 EPS. On average, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.0%. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

Analyst Ratings Changes

JNJ has been the topic of a number of research analyst reports. Sanford C. Bernstein reiterated a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Raymond James Financial lowered their price target on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research report on Monday, April 14th. Benchmark raised Johnson & Johnson to a “strong-buy” rating in a research report on Thursday, April 24th. Royal Bank Of Canada increased their target price on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research note on Thursday, July 17th. Finally, Guggenheim reaffirmed a “neutral” rating and issued a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.